KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

被引:11
作者
Sullivan, I. [1 ]
Salazar, J. [2 ,3 ]
Arqueros, C. [1 ]
Andres, M. [1 ]
Sebio, A. [1 ]
Majem, M. [1 ]
Szafranska, J. [4 ]
Martinez, E. [5 ]
Paez, D. [1 ]
Lopez-Pousa, A. [1 ]
Baiget, M. [2 ,3 ]
Barnadas, A. [1 ,6 ]
机构
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Genet Dept, St Antoni Maria Claret 167, Barcelona 08025, Spain
[3] CIBERER, U 705, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Thorac Surg Dept, Barcelona, Spain
[6] UAB, Barcelona, Spain
关键词
Resectable non-small cell lung cancer; Prognostic marker; VEGF pathway; KRAS; Genetic variants; ENDOTHELIAL GROWTH-FACTOR; PHARMACOGENETIC FACTORS; PATHWAY POLYMORPHISMS; VEGF POLYMORPHISMS; EXPRESSION; SURVIVAL; ANGIOGENESIS; CHEMOTHERAPY; ASSOCIATION; BEVACIZUMAB;
D O I
10.1007/s12094-017-1620-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Several angiogenic prognostic markers are under investigation because of their potential clinical utility, aiming to improve patient outcomes. We hypothesized that genetic variant in the VEGF pathway could be used as prognostic markers of survival in non-small cell lung cancer (NSCLC) patients undergoing pulmonary resection. Methods We evaluated the relationship between genetic variants in the VEGF pathway and relapse-free survival (RFS, main endpoint) and overall survival (OS, secondary endpoint) among 131 patients with stage I-III NSCLC treated with surgical resection from 2009 to 2013. Clinical, pathological and surgical data were prospectively collected. Twenty-five variants in sixteen relevant genes were selected and genotyped in tumor samples by real time PCR. The Kaplan-Meier method with the log-rank test and Cox's regression models were used for RFS and OS analyses. Results With a median follow-up of 36 (min = 2.8; max = 67.4) months, there were 31 (24%) relapses and 31 (24%) deaths. Overall, median RFS was not reached and median OS was 65 [95% confidence interval (CI) 56-75] months. The KRAS rs1137282 and PIK3C2A rs4356203 variants were significantly associated with RFS. For KRAS rs1137282, the 3-year RFS was 76% [95% CI 64-84%] in patients harboring an A/A genotype compared to 53% [95% CI 37-69%] in patients harboring an A/G or G/G genotype (p = 0.02). For PIK3C2A rs4356203, patients with an A/A or an A/G genotype had a 3-year RFS of 72% [95% CI 58-76%], whereas in patients with a G/G genotype was 49% [95% CI 28-70%] (p = 0.02). These associations remained statistically significant after adjusting for all the relevant clinical parameters in the multivariable analysis. Conclusion Genetic variants in VEGF pathway may be associated with recurrence in stage I-III NSCLC. Specifically, the KRAS rs1137282 could be considered as a prognostic factor for recurrence in resectable NSCLC patients. Although PIK3C2A rs4356203 was associated with RFS, further analyses are necessary to confirm these data.
引用
收藏
页码:884 / 890
页数:7
相关论文
共 50 条
  • [41] Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer
    Cathcart, Mary-Clare
    Gately, Kathy
    Cummins, Robert
    Kay, Elaine
    O'Byrne, Kenneth J.
    Pidgeon, Graham P.
    MOLECULAR CANCER, 2011, 10
  • [42] Microvessel density as a prognostic factor in non-small cell lung cancer: a meta-analysis
    Zhang, Jing
    Ma, Xuelei
    Li, Yanyan
    Song, Yanlin
    Ma, Guangzhi
    Huang, Jingwen
    Zhu, Chenjing
    Liu, Ming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (09): : 17676 - 17689
  • [43] Clinical and Molecular Predictors of Recurrence in Stage I Non-Small Cell Lung Cancer
    Starnes, Sandra L.
    Pathrose, Peterson
    Wang, Jiang
    Succop, Paul
    Morris, John C.
    Bridges, James
    Kupert, Elena Y.
    Anderson, Marshall
    ANNALS OF THORACIC SURGERY, 2012, 93 (05) : 1606 - 1613
  • [44] Predictive importance of galectin-3 for recurrence of non-small cell lung cancer
    Kataoka, Yoko
    Igarashi, Tomoyuki
    Ohshio, Yasuhiko
    Fujita, Takuya
    Hanaoka, Jun
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2019, 67 (08) : 704 - 711
  • [45] Immunotherapy for non-small cell lung cancer
    Kagamu, Hiroshi
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 307 - 312
  • [46] Clinical significance of the preoperative prognostic nutritional index in patients with resectable non-small cell lung cancer: a multicenter study
    Takahashi, Mamoru
    Aoyama, Akihiro
    Hamaji, Masatsugu
    Sozu, Takashi
    Kobayashi, Masashi
    Nakagawa, Tatsuo
    Ishikawa, Masashi
    Miyahara, Ryo
    Huang, Cheng-long
    Fujinaga, Takuji
    Sakai, Hiroaki
    Katakura, Hiromichi
    Sonobe, Makoto
    Okumura, Norihito
    Kayawake, Hidenao
    Menju, Toshi
    Miyamoto, Ei
    Miyata, Ryo
    Okada, Harutaro
    Kono, Tomoya
    Sumitomo, Ryota
    Date, Naoki
    Fukada, Takehisa
    Matsumoto, Akira
    Sakaguchi, Yasuto
    Date, Hiroshi
    SURGERY TODAY, 2025,
  • [47] Emerging angiogenesis inhibitors for non-small cell lung cancer
    Malapelle, Umberto
    Rossi, Antonio
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (02) : 71 - 81
  • [48] BIBF 1120 for the treatment of non-small cell lung cancer
    Reck, Martin
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (06) : 789 - 794
  • [49] Bevacizumab and non-small cell lung cancer: a new step?
    Perol, M.
    Arpin, D.
    REVUE DES MALADIES RESPIRATOIRES, 2009, 26 (02) : 125 - 138
  • [50] The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients
    Camps, Carlos
    Jantus-Lewintre, Eloisa
    Cabrera, Andrea
    Blasco, Ana
    Sanmartin, Elena
    Gallach, Sandra
    Caballero, Cristina
    del Pozo, Nieves
    Rosell, Rafael
    Guijarro, Ricardo
    Sirera, Rafael
    LUNG CANCER, 2011, 72 (03) : 365 - 369